P3 Health Partners Inc. (PIII)
| Market Cap | 29.04M -53.8% |
| Revenue (ttm) | 1.50B +2.8% |
| Net Income | -108.01M |
| EPS | -32.73 |
| Shares Out | 7.26M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,345 |
| Open | 3.980 |
| Previous Close | 4.030 |
| Day's Range | 3.790 - 4.160 |
| 52-Week Range | 1.520 - 16.890 |
| Beta | 1.69 |
| Analysts | Buy |
| Price Target | 18.00 (+350.02%) |
| Earnings Date | Nov 9, 2026 |
About PIII
P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. The company was founded in 2020 and is based in Henderson, Nevada.
Financial Performance
In 2025, P3 Health Partners's revenue was $1.46 billion, a decrease of -2.76% compared to the previous year's $1.50 billion. Losses were -$147.95 million, 8.91% more than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for PIII stock is "Buy." The 12-month stock price target is $18.0, which is an increase of 350.02% from the latest price.
News
P3 Health Partners Schedules Third Quarter 2026 Earnings Release and Conference Call
HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced that the Co...
P3 Health Partners Transcript: The ThinkEquity Conference
The turnaround delivered profitability, with 2026 adjusted EBITDA guidance raised to a $95M midpoint and revenue guided to $1.5B–$1.6B. Integrated plan services and continued care-model improvements underpin further upside and a targeted market of ~6M patients.
P3 Health Partners Registration statement: Registration filing
P3 Health Partners filed a registration statement on October 15, 2026, providing details about a securities offering with the SEC.
P3 Health Partners files to sell 15.64M shares of Class A common for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 15.64M shares of Class A common stock. The company is not…
P3 Health Partners appoints Millie as Chief Clinical Officer
P3 Health Partners (PIII) announced the appointment of Dr. Michael Millie as Chief Clinical Officer, effective October 12, 2026. Dr. Millie most recently served as a Chief Medical Officer, overseeing…
P3 Health Partners Inc. Announces Appointment of Chief Clinical Officer
HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced the appoint...
FORE Biotherapeutics to Participate in Upcoming Investor Conferences
PHILADELPHIA--(BUSINESS WIRE)--FORE Biotherapeutics today announced that the Company will participate at the following investor conferences: Wells Fargo 21st Annual Healthcare Conference. The Company ...
FORE Biotherapeutics Announces Positive Outcome from First Planned Interim Efficacy Analysis from FORTE Basket Study Evaluating Plixorafenib Monotherapy in Advanced Solid Tumors with BRAF Fusions
PHILADELPHIA--(BUSINESS WIRE)--FORE Biotherapeutics, a registration stage company dedicated to developing targeted therapies to treat patients with cancer, today announced that following the first of ...
P3 Health Partners price target raised to $23 from $14 at Lake Street
Lake Street raised the firm’s price target on P3 Health Partners (PIII) to $23 from $14 and keeps a Buy rating on the shares. With the conversion of debt to…
P3 Health Partners Earnings Call Transcript: Q2 2026
Q2 2026 delivered strong financial results with $54M adjusted EBITDA and improved medical cost trends, driven by operational execution, payer settlements, and expanded clinical programs. Full-year EBITDA guidance was raised to $80–$110M, reflecting confidence in durable earnings.
P3 Health Partners Earnings release: Q2 2026
P3 Health Partners released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
P3 Health Partners Quarterly report: Q2 2026
P3 Health Partners has published its Q2 2026 quarterly earnings report on August 10, 2026.
P3 Health Partners reports Q2 EPS (63c), consensus ($1.90)
Reports Q2 revenue $386.38M, consensus $377.95M. “Q2 demonstrates that the business is now executing according to our plan. We delivered $54 million of adjusted EBITDA, with the core business driving…
P3 Health Partners sees FY26 revenue $1.5B-$1.6B, consensus $1.52B
Sees FY26 adjusted EBITDA $80M-$110M.
P3 Health Partners Announces Second Quarter 2026 Results
HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced its financi...
P3 Health Partners Slides: Investor presentation
P3 Health Partners has posted slides in relation to its latest quarterly earnings report, which was published on August 10, 2026.
P3 Health Partners Schedules Second Quarter 2026 Earnings Release and Conference Call
HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced that the Co...
P3 Health Partners Transcript: AGM 2026
The meeting covered officer introductions, voting on four key proposals, and confirmation of quorum. All proposals were approved, with final results to be published in a Form 8-K. No questions were submitted by stockholders.
P3 Health Partners price target raised to $14 from $3 at TD Cowen
TD Cowen raised the firm’s price target on P3 Health Partners (PIII) to $14 from $3 and keeps a Hold rating on the shares. The firm said they reported 1Q26…
P3 Health Partners Inc trading resumes
09:50 EDT P3 Health Partners (PIII) Inc trading resumes
P3 Health Partners Inc trading halted, volatility trading pause
09:40 EDT P3 Health Partners (PIII) Inc trading halted, volatility trading pause
P3 Health Partners price target raised to $14 from $4 at Lake Street
Lake Street raised the firm’s price target on P3 Health Partners (PIII) to $14 from $4 and keeps a Buy rating on the shares. The transitional year of 2025 is…
P3 Health Partners reports Q1 EPS 32c vs ($6.28) last year
Reports Q1 revenue $386M vs $373M last year. “Q1 represents a meaningful turning point for the business. The $26 million of adjusted EBITDA we delivered this quarter reflects the cumulative…
P3 Health Partners sees FY26 revenue $1.5B-$1.65B
Sees FY26 adjusted EBITDA $20M-$60M
P3 Health Partners Earnings Call Transcript: Q1 2026
Q1 delivered $26M adjusted EBITDA, exceeding expectations, with revenue up year-over-year despite lower membership. Structural improvements, disciplined execution, and favorable macro trends led to a raised 2026 outlook of $20–$60M adjusted EBITDA.